CoChat

Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study

Open access
Hepprich, Matthias, Zillig, Daniela, Florian-Reynoso, Manuel A., Donath, Marc Y., Rudofsky, Gottfried · 2021 · Diabetes Therapy
Cited by 18

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Despite expert consensus guidelines, data is scarce on how to switch patients with type 2 diabetes when treatment with glucagon-like peptide 1 (GLP-1) receptor agonists is not effective and whether a switch to semaglutide brings any benefit on glucose and weight control for patients with type 2 diabetes. METHODS: Retrospective cohort analysis of patients with type 2 diabetes who were switched from any GLP-1 agonist in a stable dose to subcutaneously administered semaglutide. Primary endpoint was change of glycated haemoglobin (HbA1c) at 6 months. Secondary endpoints were weight, body mass index (BMI), heart rate, blood pressure and adverse events. RESULTS: ) were included. HbA1c was significantly lower 6 months after switching to semaglutide (7.3%; 56 mmol/l). Median body weight was significantly lower at 3 months (94 kg) and 6 months (93 kg) compared to baseline (98 kg). An equipotential dose switch of semaglutide was used in 61 patients (79%) and a stepwise initiation approach was used in 16 patients (21%). Both treatment regimens improved glucose control and weight. Side effects occurred in 28 patients (36%). CONCLUSION: Switching to semaglutide from established GLP-1 analogue therapy improved HbA1c and body weight. Both equipotential and stepwise dosing initiation appear to be effective and well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-021-01016-y

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 18

Metadata

Authors
Hepprich, M., Zillig, D., Florian-Reynoso, M. A., Donath, M. Y., & Rudofsky, G.
Venue
Diabetes Therapy
Published
2021-02-22
Volume
12
Issue
3
Pages
943-954
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3132182234
Cited by
18
References
9
FWCI
2.18
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. https://app.cochat.ai/papers/10.1007/s13300-021-01016-y
The paper
Hepprich, M., Zillig, D., Florian-Reynoso, M. A., Donath, M. Y., & Rudofsky, G. (2021). Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Therapy. https://doi.org/10.1007/s13300-021-01016-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.